Wegovy

The most common side effects with Wegovy are gastrointestinal, such as nausea and diarrhoea, and these often lessen over time. Other medicines have different risks: Orlistat can cause oily stools, Mysimba may raise blood pressure, and phentermine (not used in the UK) carries cardiovascular risks. Understanding risk in context All weight-loss medicines come with benefits and risks. Doctors weigh these carefully before prescribing, taking into account a person’s health conditio

Yes, Wegovy has strong evidence in people with type 2 diabetes, cardiovascular disease, and sleep apnoea, where weight loss can improve outcomes. Other drugs may be chosen if semaglutide is unsuitable, but few have shown the same range of benefits across multiple health conditions. Why certain conditions matter Weight-related health problems often go beyond the number on the scales. People with obesity are more likely to develop type 2 diabetes, cardiovascular disease, and sl

Yes, Wegovy has strong evidence in people with type 2 diabetes, cardiovascular disease, and sleep apnoea, where weight loss can improve...

The most common side effects with Wegovy are gastrointestinal, such as nausea and diarrhoea, and these often lessen over time. Other...

The SELECT trial showed semaglutide 2.4 mg (Wegovy) reduced the risk of major heart problems in people with overweight or obesity and...

No, even though both contain semaglutide, they are licensed for different uses and come in different devices and doses. Doctors may...

The SELECT trial showed semaglutide 2.4 mg (Wegovy) reduced the risk of major heart problems in people with overweight or obesity and cardiovascular disease. Orlistat, while useful for modest weight loss, has not shown the same scale of cardiovascular benefits in large outcome studies. Two very different medicines Wegovy and Orlistat are both prescribed for weight management, but they work in completely different ways. Wegovy (semaglutide) is a GLP-1 receptor agonist that red

No, even though both contain semaglutide, they are licensed for different uses and come in different devices and doses. Doctors may...

In the UK, coverage depends on NHS commissioning rather than insurance, and NICE now recommends Wegovy within specialist services....

In the UK, coverage depends on NHS commissioning rather than insurance, and NICE now recommends Wegovy within specialist services. Saxenda has more limited NHS use. In private healthcare or in other countries, coverage varies by insurer, but newer guidance tends to prioritise Wegovy because of its stronger results. The UK context: NHS commissioning, not insurance Unlike in the United States, where health insurance policies determine which drugs are covered, the UK relies on t

Wegovy works directly on appetite signals in the brain, helping people feel full sooner and think less about food. Other medicines act...

Wegovy works directly on appetite signals in the brain, helping people feel full sooner and think less about food. Other medicines act...

Wegovy has shown sustained weight loss of around 15% at 68 weeks, and many participants maintained benefits at two years. Qsymia (not...

Survey and trial follow-ups suggest people report higher satisfaction with Wegovy than older GLP-1 drugs, mainly because of greater...

Wegovy has shown sustained weight loss of around 15% at 68 weeks, and many participants maintained benefits at two years. Qsymia (not...

Survey and trial follow-ups suggest people report higher satisfaction with Wegovy than older GLP-1 drugs, mainly because of greater...

Yes, NICE guidance states that Wegovy can be offered to adults with a BMI over 35 and at least one weight-related condition, or sometimes...

Yes, NICE guidance states that Wegovy can be offered to adults with a BMI over 35 and at least one weight-related condition, or sometimes with a BMI over 30 if criteria are met. Other drugs, like Saxenda or Mysimba, have similar but slightly different BMI thresholds, while diabetes drugs like Trulicity are prescribed on blood sugar criteria instead. Wegovy and its eligibility rules In the UK, NICE sets out clear criteria for who can be prescribed Wegovy. It is recommended for

Trials such as STEP-1 and SELECT showed Wegovy not only reduced weight but also improved blood pressure, cholesterol, and markers of...

Trials such as STEP-1 and SELECT showed Wegovy not only reduced weight but also improved blood pressure, cholesterol, and markers of heart health. Other medicines, like Saxenda, also improve some metabolic measures but to a smaller extent, and drugs like Orlistat mainly affect fat absorption rather than broad cardiometabolic outcomes. Why metabolic health matters Weight management is not just about the number on the scales. Many of the health risks linked to excess weight — i